# Research Report: Metformin

**Generated:** 2025-12-25 15:24:58
**Report ID:** 94d856f3-a097-4e82-a14d-6df96442d16f

---

## Table of Contents

1. iqvia_insights
2. clinical_trials
3. patent_landscape

---

## iqvia_insights

**Market Analysis for Metformin**

ğŸ“Š **Current Market Size:** $10,234.14M
ğŸ“ˆ **5-Year CAGR:** 9.44%
ğŸ¯ **2028 Forecast:** $14,678.49M

**Top Markets:** Germany, UK, India
**Market Leader:** Gilead Sciences

The Oncology segment shows strong growth trajectory.

---

## clinical_trials

**Clinical Trials Analysis: Metformin**

ğŸ“Š **Total Trials:** 10
âœ… **Active Trials:** 7
ğŸ‘¥ **Total Enrollment:** 9,042 patients
ğŸ¯ **Indication:** Oncology

**Phase Distribution:**
â€¢ Phase 1: 2 trials
â€¢ Phase 1/2: 1 trials
â€¢ Phase 2: 2 trials
â€¢ Phase 2/3: 2 trials
â€¢ Phase 3: 2 trials
â€¢ Phase 4: 1 trials

**Top Sponsors:**
â€¢ Bayer
â€¢ GSK
â€¢ Novartis

**Development Status:**
â€¢ Early development stage
â€¢ Multiple sponsors active

---

## patent_landscape

**Patent Landscape Analysis: Metformin**

ğŸ“‹ **Total Patents:** 4
âœ… **Active Patents:** 3
ğŸ“… **Earliest Expiry:** 2035-05-14
âš–ï¸ **FTO Status:** Clear ğŸŸ¢ Clear
ğŸ”„ **Litigation History:** No

**Key Patent Holders:**
â€¢ Bayer
â€¢ AbbVie
â€¢ Bristol-Myers Squibb

**Strategic Implications:**
â€¢ Strong IP protection continues
â€¢ FTO pathway available

---

## Data Tables

### Market Size Analysis - Metformin

| Year | Market Size (USD M) | Growth Rate (%) |
| --- | --- | --- |
| 2019 | 6520.24 | 6.9 |
| 2020 | 7075.21 | 8.5 |
| 2021 | 7941.91 | 12.2 |
| 2022 | 8791.2 | 10.7 |
| 2023 | 9562.5 | 8.8 |
| 2024 | 10234.14 | 7.0 |

### Clinical Trials - Metformin

| NCT ID | Phase | Status | Sponsor | Enrollment | Start Date |
| --- | --- | --- | --- | --- | --- |
| NCT99978102 | Phase 1 | Not yet recruiting | Eli Lilly | 1207 | 2024-01-30 |
| NCT43344698 | Phase 4 | Recruiting | Johnson & Johnson | 414 | 2024-06-11 |
| NCT66210030 | Phase 2/3 | Not yet recruiting | Eli Lilly | 294 | 2021-11-10 |
| NCT72018215 | Phase 2 | Recruiting | GSK | 1684 | 2025-04-01 |
| NCT56945997 | Phase 2 | Recruiting | Bayer | 1107 | 2025-08-20 |
| NCT62958202 | Phase 3 | Recruiting | Merck | 799 | 2022-09-21 |
| NCT82962239 | Phase 3 | Active, not recruiting | Novartis | 663 | 2024-06-23 |
| NCT63230357 | Phase 1/2 | Active, not recruiting | Bayer | 962 | 2022-11-30 |
| NCT63905662 | Phase 2/3 | Completed | AstraZeneca | 922 | 2025-05-10 |
| NCT49576497 | Phase 1 | Recruiting | Novartis | 990 | 2023-11-07 |

### Patent Portfolio - Metformin

| Patent Number | Type | Assignee | Filing Date | Expiry Date | Status |
| --- | --- | --- | --- | --- | --- |
| US11028106 | Process | AbbVie | 2021-04-01 | 2041-03-27 | Active |
| US10829180 | Use | Bayer | 2010-02-13 | 2030-02-08 | Expired |
| US11277185 | Use | Bristol-Myers Squibb | 2015-05-19 | 2035-05-14 | Active |
| US8273836 | Formulation | Bayer | 2024-04-22 | 2044-04-17 | Active |

## References

- WIPO
- IQVIA MIDAS Database
- IQVIA National Sales Perspectives
- WHO ICTRP
- USPTO Patent Database
- European Patent Office
- ClinicalTrials.gov
- EU Clinical Trials Register
